Tenderwize
Retour à la recherche

Open-house pharmaceutical discount agreements for Atovaquone

AOK Bayern - Die Gesundheitskasse·München, Germany·Deadline Mar 03, 2028 · 552 days left·Open·Supplies·Framework
Inscrivez-vous pour sauvegarderOpen documents
Titre original de l'avis

Germany – Pharmaceutical products – Open house Arzneimittelrabattverträge Atovaquon, ATC P01AX06

58/100

Score d'opportunité

Needs reviewMedium complexity
SuppliesFrameworkOpen
Pourquoi ce score ?

Opportunité

58 / 100

Complexité

45 / 100

Facteurs de risque

The notice uses an open procedure form, but both structured data and XML state the substance is an open-house model out...

Timing is strict: to start on the next month’s first day, complete documents must arrive by the 3rd of the month; for p...

Analyse approfondie du portefeuille

Analyse approfondie de l'adéquation entreprise

Utilise:

  • Description
  • Industries & Services
  • Capabilities
  • Market & Experience
  • Certifications

Aperçu

Moderate opportunity

Faits clés

  • Framework procurement
  • Supplies contract
  • 1 lot
  • Duration until Apr 2028
  • Non-exclusive pharmaceutical discount agreement for Atovaquone (ATC P01AX06).
  • Open-house accession model with identical, pre-defined contractual terms for all eligible companies.
Afficher le résumé complet

This is an open-house supply arrangement for pharmaceutical discount agreements on Atovaquone (ATC P01AX06) by AOK Bayern. It is not a competitive award procedure in substance, but an accession model with identical non-negotiable terms for all eligible pharmaceutical companies. Contracting is possible until 03.03.2028, with possible start dates on the first day of the following month if complete documents are received by the 3rd, or the month after if later. No contract value is stated.

Risques

The notice uses an open procedure form, but both structured data and XML state the substance is an open-house model out...

Timing is strict: to start on the next month’s first day, complete documents must arrive by the 3rd of the month; for p...

L'analyse peut être incomplète

Seule une partie des documents de consultation a été analysée. Des exigences, certificats ou documents de soumission supplémentaires peuvent exister dans les documents restants.

Exigences clés

Technical

  • The contract and the annex 'Festlegung der vertragsgegenständlichen Arzneimittel' must be completed and signed.

Eligibility

  • Only pharmaceutical companies are eligible as potential contract partners.

Administrative

  • A signed declaration of reliability (Eigenerklärung zur Zuverlässigkeit) must be submitted.

Acheteur

Localisation

München, DEU

Site web

www.aok.de

Profil acheteur

Ouvrir le profil

Identifiant

DE811695320

Activité

Health

Lots (1)

LOT-0001

Open-house pharmaceutical discount agreements for Atovaquone

Single lot covering non-exclusive open-house Rabattverträge for the active substance Atovaquone (ATC P01AX06). The lot is for supply-type pharmaceutical products in Germany (Bavaria/Munich contracting authority). Terms are fixed and non-individually negotiable.

SuppliesFrameworkEU fundedElectronic submission

Localisation

DE212, Germany

Durée

Apr 2026 - Apr 2028

Catégorie

Pharmaceutical products

Date limite

Deadline Mar 03, 2028

Détails de la procédure

Date de publication
15 Mar 2026
Langues
German

Métadonnées de référence

Base juridique
32014L0024

Identifiants de référence

ID de l'appel d'offres
179704-2026

Documents (2)

Document de consultation 1Portail de soumission 1

Appels d'offres similaires

Bulgaria – Pharmaceutical products – Динамична система за покупки за доставка на лекарствени продукти за Медицински институт на МВР

Jul 9

Germany – Pharmaceutical products – Abschluss nicht exkl. Arzneimittel-Rabattvereinb. nach § 130a Abs. 8 SGB V im Wege eines Open-House-Modells über Arzneimittel mit dem Handelsnamen Oralair(R) (ATC-Code nach WHO: V01AA02)

Aug 31

Germany – Pharmaceutical products – Abschluss nicht exkl. Arzneimittel-Rabattvereinb. nach § 130a Abs. 8 SGB V im Wege eines Open-House-Modells zum Wirkstoff Ipratropiumbromid (ATC-Code nach WHO: R03BB01)

Sep 30

Denmark – Pharmaceutical products – Amgros 2027 1.1170.a

Sep 3

Germany – Pharmaceutical products – Abschluss nicht exkl. Arzneimittel-Rabattvereinb. nach § 130a Abs. 8 SGB V im Wege eines Open-House-Modells über Arzneimittel mit dem Handelsnamen Orylmyte(R) (ATC-Code nach WHO: V01AA03)

Aug 31

Germany – Pharmaceutical products – Open House Biologika Rabattverträge 2026 - 27 - Follitropin delta

Aug 30